trospium (Sanctura, Spasmoplex, Spasmex, Relaspium)
Jump to navigation
Jump to search
Introduction
Tradenames: Sanctura
Indications
Contraindications
- patients with GI motility problems
- myasthenia gravis
- ulcerative colitis
Dosage
Pharmacokinetics
- not metabolized
- does not cross blood brain barrier
Adverse effects
- gastroparesis
- lower incidence of dry mouth than oxybutinin[3]
Drug interactions
Mechanism of action
- primarily antagonizes muscarinic M2 & M3 receptors
- inhibits bladder contraction & urge to void
More general terms
References
- ↑ Prescriber's Letter 11(9): 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200910&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Prescriber's Letter 12(2): 2005 Antimuscarinic Medications for Overactive Bladder Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210209&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Erdem M & Chu FM Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med 2006;119(3A):295
- ↑ 4.0 4.1 Prescriber's Letter 15(1): 2008 New Dosage Form: Sanctura XR (Trospium Extended-Release) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240108&pb=PRL (subscription needed) http://www.prescribersletter.com